The α2‐adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti‐parkinsonian actions of L‐dopa in the MPTP‐lesioned primate model of Parkinson's disease
Identifieur interne : 004C22 ( Main/Exploration ); précédent : 004C21; suivant : 004C23The α2‐adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti‐parkinsonian actions of L‐dopa in the MPTP‐lesioned primate model of Parkinson's disease
Auteurs : Brian Henry [Royaume-Uni] ; Susan H. Fox [Royaume-Uni] ; David Peggs [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 1999-09.
English descriptors
- KwdEn :
Abstract
Dopamine replacement therapy in patients with Parkinson's disease is plagued by the emergence of abnormal involuntary movements known as L‐dopa‐induced dyskinesias. It has been demonstrated that yohimbine can reduce L‐dopa‐induced dyskinesia in the MPTP‐lesioned primate model of Parkinson's disease. Yohimbine is, among other things, an alpha‐adrenergic receptor antagonist. In this study, we demonstrate that the selective and potent α2‐adrenergic receptor antagonist idazoxan reduces L‐dopa‐induced dyskinesia in the MPTP‐lesioned marmoset model of Parkinson's disease. The α2‐adrenergic receptor antagonists rauwolscine and yohimbine also reduce L‐dopa‐induced dyskinesia. Furthermore, we demonstrate that coadministration of idazoxan with L‐dopa can provide an anti‐parkinsonian action more than twice the length of that seen with L‐dopa alone. However, idazoxan as a monotherapy displayed no anti‐parkinsonian actions. We propose that idazoxan in combination with L‐dopa may provide a novel approach to the treatment of Parkinson's disease that will not only reduce the dyskinetic side effects, but extend the anti‐parkinsonian actions of L‐dopa. Idazoxan, as an adjunct to dopamine replacement, may prove useful in the treatment of parkinsonian patients at all stages of disease progression.
Url:
DOI: 10.1002/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000A14
- to stream Istex, to step Curation: 000A14
- to stream Istex, to step Checkpoint: 003388
- to stream Main, to step Merge: 007920
- to stream Main, to step Curation: 004C22
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The α2‐adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti‐parkinsonian actions of L‐dopa in the MPTP‐lesioned primate model of Parkinson's disease</title><author><name sortKey="Henry, Brian" sort="Henry, Brian" uniqKey="Henry B" first="Brian" last="Henry">Brian Henry</name></author><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name></author><author><name sortKey="Peggs, David" sort="Peggs, David" uniqKey="Peggs D" first="David" last="Peggs">David Peggs</name></author><author><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DCF36F53CD7DADB029A8D5715C8A6CED0975ACEE</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1002/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7</idno><idno type="url">https://api.istex.fr/document/DCF36F53CD7DADB029A8D5715C8A6CED0975ACEE/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000A14</idno><idno type="wicri:Area/Istex/Curation">000A14</idno><idno type="wicri:Area/Istex/Checkpoint">003388</idno><idno type="wicri:doubleKey">0885-3185:1999:Henry B:the:adrenergic:receptor</idno><idno type="wicri:Area/Main/Merge">007920</idno><idno type="wicri:Area/Main/Curation">004C22</idno><idno type="wicri:Area/Main/Exploration">004C22</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The α2‐adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti‐parkinsonian actions of L‐dopa in the MPTP‐lesioned primate model of Parkinson's disease</title><author><name sortKey="Henry, Brian" sort="Henry, Brian" uniqKey="Henry B" first="Brian" last="Henry">Brian Henry</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Organon Laboratories Limited, Department of Pharmacology, Newhouse, Lanarkshire, Scotland</wicri:regionArea><wicri:noRegion>Scotland</wicri:noRegion></affiliation></author><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Manchester Movement Disorder Laboratory, 1.124 Division of Neuroscience, School of Biological Sciences, University of Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="nation">Angleterre</region><region nuts="2" type="region">Grand Manchester</region></placeName><orgName type="university">Université de Manchester</orgName></affiliation></author><author><name sortKey="Peggs, David" sort="Peggs, David" uniqKey="Peggs D" first="David" last="Peggs">David Peggs</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Manchester Movement Disorder Laboratory, 1.124 Division of Neuroscience, School of Biological Sciences, University of Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="nation">Angleterre</region><region nuts="2" type="region">Grand Manchester</region></placeName><orgName type="university">Université de Manchester</orgName></affiliation></author><author><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Manchester Movement Disorder Laboratory, 1.124 Division of Neuroscience, School of Biological Sciences, University of Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="nation">Angleterre</region><region nuts="2" type="region">Grand Manchester</region></placeName><orgName type="university">Université de Manchester</orgName></affiliation></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Manchester Movement Disorder Laboratory, 1.124 Division of Neuroscience, School of Biological Sciences, University of Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="nation">Angleterre</region><region nuts="2" type="region">Grand Manchester</region></placeName><orgName type="university">Université de Manchester</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="1999-09">1999-09</date><biblScope unit="vol">14</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="744">744</biblScope><biblScope unit="page" to="753">753</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">DCF36F53CD7DADB029A8D5715C8A6CED0975ACEE</idno><idno type="DOI">10.1002/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7</idno><idno type="ArticleID">MDS1006</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐lesioned marmoset</term><term>Idazoxan</term><term>L‐Dopa‐induced dyskinesia</term><term>Parkinson's disease</term><term>α2‐Adrenergic receptor antagonists</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dopamine replacement therapy in patients with Parkinson's disease is plagued by the emergence of abnormal involuntary movements known as L‐dopa‐induced dyskinesias. It has been demonstrated that yohimbine can reduce L‐dopa‐induced dyskinesia in the MPTP‐lesioned primate model of Parkinson's disease. Yohimbine is, among other things, an alpha‐adrenergic receptor antagonist. In this study, we demonstrate that the selective and potent α2‐adrenergic receptor antagonist idazoxan reduces L‐dopa‐induced dyskinesia in the MPTP‐lesioned marmoset model of Parkinson's disease. The α2‐adrenergic receptor antagonists rauwolscine and yohimbine also reduce L‐dopa‐induced dyskinesia. Furthermore, we demonstrate that coadministration of idazoxan with L‐dopa can provide an anti‐parkinsonian action more than twice the length of that seen with L‐dopa alone. However, idazoxan as a monotherapy displayed no anti‐parkinsonian actions. We propose that idazoxan in combination with L‐dopa may provide a novel approach to the treatment of Parkinson's disease that will not only reduce the dyskinetic side effects, but extend the anti‐parkinsonian actions of L‐dopa. Idazoxan, as an adjunct to dopamine replacement, may prove useful in the treatment of parkinsonian patients at all stages of disease progression.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Manchester</li></region><settlement><li>Manchester</li></settlement><orgName><li>Université de Manchester</li></orgName></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Henry, Brian" sort="Henry, Brian" uniqKey="Henry B" first="Brian" last="Henry">Brian Henry</name></noRegion><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name><name sortKey="Peggs, David" sort="Peggs, David" uniqKey="Peggs D" first="David" last="Peggs">David Peggs</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004C22 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004C22 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:DCF36F53CD7DADB029A8D5715C8A6CED0975ACEE
|texte= The α2‐adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti‐parkinsonian actions of L‐dopa in the MPTP‐lesioned primate model of Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |